The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. [PDF]
Crucitta S +17 more
europepmc +1 more source
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang +11 more
wiley +1 more source
Double-balloon (CANDIS) Retrograde Transvenous Obliteration Improves Hepatic Functional Reserve Compared with the Conventional Method. [PDF]
Aoki T +9 more
europepmc +1 more source
Prognostic value of systemic inflammation indices in patients with metastatic colorectal cancer treated with TAS-102: a single-center retrospective real-world study. [PDF]
Liu M, Cui Y, Chen L, Zhang F, Liu F.
europepmc +1 more source
Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. [PDF]
Ramidi GR, Yadav R, Patnaik A, Sunny G.
europepmc +1 more source
Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer. [PDF]
Savvidou Α +10 more
europepmc +1 more source
Lessons from Denmark for community-based governance of urban heat networks. [PDF]
Sampson E, Makuch Z.
europepmc +1 more source
openaire +1 more source

